USRM US Stem Cell Inc (CE)

SUNRISE, FL--(Marketwired - May 15, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today its financial results for the first quarter of 2014.

Product revenues during the first quarter of 2014 were $322,572, compared to $4,192 during the first quarter of 2013. In addition, this is a 98% increase over the fourth quarter revenue of $157,055. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell system and related supplies, and cell culturing and banking services. Cost of sales consists of the costs associated with the production of MyoCath, laboratory supplies necessary for laboratory services, production of AdipoCell systems and materials, and clinic supplies required for patient studies. Cost of sales was $94,446 in the three-month period ended March 31, 2014, which is a gross margin of 71%.

"A solid team and business plan has led to this strong start to 2014," said Mike Tomas, President and Chief Executive Officer of Bioheart. "We have already made great progress and are poised for continued momentum."

About Bioheart, Inc. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.

Media Contact: Carissa Matton Bioheart, Inc. 13794 NW 4th Street, Suite 212 Sunrise, Florida 33325 Phone: 772.285.8511 cmatton@bioheartinc.com

US Stem Cell (CE) (USOTC:USRM)
Historical Stock Chart
From Oct 2024 to Nov 2024

US Stem Cell (CE) (USOTC:USRM)
Historical Stock Chart
From Nov 2023 to Nov 2024